[Update on asthma 2024 - what the ENT specialist needs to know]. / Aktuelles zum Asthma 2024 was der HNO-Arzt wissen muss.
Laryngorhinootologie
; 103(3): 219-230, 2024 03.
Article
em De
| MEDLINE
| ID: mdl-38437838
ABSTRACT
The lifetime prevalence of 8.6% of asthma in Germany reflects the high medical and socioeconomic impact of the disease. Asthma treatment goals have changed during the last decades from symptom control to symptom prevention, with highly effective, disease-modifying anti-asthmatic drugs (DMAADs) aiming at asthma remission. In order to achieve this goal, phenotyping of patients (including an evaluation of allergies and type 2 biomarkers) is crucial for personalized treatment. The identification and effective treatment of concomitant diseases, such as allergic rhinitis or chronic rhinosinusitis with nasal polyps (CRSwNP), plays a major role for successful treatment. This underlines the importance of interdisciplinary collaboration of otolaryngologists and respiratory physicians in the management of patients with asthma. This CME article informs the reader about current guidelines on the diagnosis and treatment of asthma, focusing on clinically relevant recommendations for ENT physicians.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Asma
/
Rinite Alérgica
Limite:
Humans
País/Região como assunto:
Europa
Idioma:
De
Ano de publicação:
2024
Tipo de documento:
Article